November 30, 2020
Strong CERAMENT data published in Science Advances
Media
November 30, 2020
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
November 30, 2020
Nordic Nanovector announces change of its Oslo Børs ticker symbol to “NANOV”
November 24, 2020
Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in the Journal, Pituitary
November 24, 2020
Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma
November 19, 2020
SynOx Therapeutics raises €37M in Series A Financing
November 19, 2020
INTERIM REPORT Q3 2020
November 19, 2020
Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial
November 19, 2020
Nordic Nanovector ASA: Results for the Third Quarter 2020
November 18, 2020
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
